Literature DB >> 23969201

Which drug-induced side effects would be tolerated in the prospect of seizure control?

Juri-Alexander Witt1, Christian E Elger, Christoph Helmstaedter.   

Abstract

There is ample evidence that side effects of antiepileptic pharmacotherapy negatively affect quality of life, adherence, and long-term retention. The study was set up to evaluate the anticipated tolerance of common side effects provided that a 50% or 100% reduction of seizure frequency would be achieved. An anonymous inquiry in 79 consecutive patients with epilepsy comprised questions regarding the severity of epilepsy/seizures and the perceived impact of seizures and drug treatment on daily functioning and a 10-tiered rating which assesses 11 common behavioral/psychiatric, cognitive, physiological, or physical side effects according to the degree to which they would be tolerated. Least acceptance was evident for psychiatric side effects followed by cognitive, physiological, and physical side effects. Weight gain and tiredness were the most tolerated side effects. The overall low acceptance of negative side effects was slightly higher in the case of a 100% vs. 50% seizure frequency reduction (28% vs. 21% of the maximum toleration score regarding all side effects). Surely, there is a trade-off between the severity of epilepsy, seizure control, and the acceptance of adverse treatment effects. However, the data disclose that psychiatric and cognitive side effects are least accepted. Thus, consideration of individual tolerance and monitoring of side effects in addition to seizures may increase adherence and therapy success.
© 2013.

Entities:  

Keywords:  Adverse events; Antiepileptic drugs; Cognition; Irritability; Memory; Mood; Seizure control; Treatment-emergent side effects

Mesh:

Substances:

Year:  2013        PMID: 23969201     DOI: 10.1016/j.yebeh.2013.07.013

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  10 in total

Review 1.  Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy.

Authors:  Frank M C Besag; Michael J Vasey
Journal:  Paediatr Drugs       Date:  2021-05-06       Impact factor: 3.022

2.  Acute cognitive impact of antiseizure drugs in naive rodents and corneal-kindled mice.

Authors:  Melissa L Barker-Haliski; Fabiola Vanegas; Matthew J Mau; Tristan K Underwood; H Steve White
Journal:  Epilepsia       Date:  2016-07-28       Impact factor: 5.864

3.  Neurologist-patient communication about epilepsy in the United States, Spain, and Germany.

Authors:  John M Stern; Fernando Cendes; Frank Gilliam; Patrick Kwan; Philippe Ryvlin; Joseph Sirven; Brien Smith; Aleksandra Adomas; Lauren Walter
Journal:  Neurol Clin Pract       Date:  2018-04

Review 4.  Clinical utility of eslicarbazepine: current evidence.

Authors:  Gaetano Zaccara; Fabio Giovannelli; Massimo Cincotta; Alessia Carelli; Alberto Verrotti
Journal:  Drug Des Devel Ther       Date:  2015-02-10       Impact factor: 4.162

Review 5.  Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy.

Authors:  Renato Tambucci; Claudia Basti; Maria Maresca; Giangennaro Coppola; Alberto Verrotti
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-23       Impact factor: 2.570

6.  Factors affecting adherence to antiepileptic medications among Sudanese individuals with epilepsy: A cross-sectional survey.

Authors:  Muaz A Elsayed; Nuha Musa El-Sayed; Safaa Badi; Mohamed H Ahmed
Journal:  J Family Med Prim Care       Date:  2019-07

7.  Identification and ranking of important bio-elements in drug-drug interaction by Market Basket Analysis.

Authors:  Reza Ferdousi; Ali Akbar Jamali; Reza Safdari
Journal:  Bioimpacts       Date:  2019-11-02

8.  Efficacy of levetiracetam in the treatment of pediatric epilepsy: A protocol for systematic review and meta-analysis.

Authors:  Qiming Pang; Bangtao Li; Suli Zhang; Jiaoyang Li; Shuo Gu
Journal:  Medicine (Baltimore)       Date:  2022-02-25       Impact factor: 1.817

9.  Investigation on the Anticonvulsant Potential of Luteolin and Micronized Luteolin in Adult Zebrafish (Danio rerio).

Authors:  Cristiane Garbinato; Cássia Alves Lima-Rezende; Sabrina Ester Schneider; Jefferson Pedroso; Aline E Dos Santos; Fernanda Petry; Gean Pablo S Aguiar; Liz Girardi Müller; Marcelo Lanza; Angelo Piato; J Vladimir Oliveira; Anna Maria Siebel
Journal:  Neurochem Res       Date:  2021-07-26       Impact factor: 3.996

10.  Forecasting Seizures Using Intracranial EEG Measures and SVM in Naturally Occurring Canine Epilepsy.

Authors:  Benjamin H Brinkmann; Edward E Patterson; Charles Vite; Vincent M Vasoli; Daniel Crepeau; Matt Stead; J Jeffry Howbert; Vladimir Cherkassky; Joost B Wagenaar; Brian Litt; Gregory A Worrell
Journal:  PLoS One       Date:  2015-08-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.